Sk Biopharmaceuticals Co Ltd Cash Flow Conversion Efficiency

Latest as of March 2026: 0.019x

Sk Biopharmaceuticals Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has a cash flow conversion efficiency ratio of 0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩17.92 Billion ≈ $12.14 Million USD) by net assets (₩932.05 Billion ≈ $631.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Sk Biopharmaceuticals Co Ltd (2016–2025)

Cash flow conversion efficiency of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. This chart illustrates how Sk Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 326030 stock price for real-time trading data and today's change.

Sk Biopharmaceuticals Co Ltd Cash Flow Conversion Ratio Explained

Sk Biopharmaceuticals Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Sk Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency. Also see Sk Biopharmaceuticals Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
TFS Financial Corporation NASDAQ:TFSL	0.017x
Spirit Aerosystems Holdings Inc NYSE:SPR	0.041x
Sotera Health Co NASDAQ:SHC	0.133x
Aurizon Holdings Ltd AU:AZJ	0.145x
Amentum Holdings Inc. NYSE:AMTM	0.030x
Shanghai Wanye Enterprises Co Ltd SHG:600641	-0.075x
Ningbo Orient Wires and Cables Co Ltd SHG:603606	0.194x
Grupo Aeroportuario del Centro Norte SAB de CV NASDAQ:OMAB	0.137x

Annual Cash Flow Conversion Efficiency for Sk Biopharmaceuticals Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. Review how much free cash does Sk Biopharmaceuticals Co Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩826.27 Billion ≈ $559.95 Million	₩176.33 Billion ≈ $119.50 Million	0.213x	+29.08%
2024-12-31	₩573.98 Billion ≈ $388.98 Million	₩94.90 Billion ≈ $64.31 Million	0.165x	+156.33%
2023-12-31	₩320.95 Billion ≈ $217.50 Million	₩-94.20 Billion ≈ $-63.84 Million	-0.294x	+41.90%
2022-12-31	₩316.56 Billion ≈ $214.53 Million	₩-159.92 Billion ≈ $-108.38 Million	-0.505x	-141.62%
2021-12-31	₩444.19 Billion ≈ $301.02 Million	₩-92.87 Billion ≈ $-62.94 Million	-0.209x	+62.39%
2020-12-31	₩379.07 Billion ≈ $256.89 Million	₩-210.73 Billion ≈ $-142.81 Million	-0.556x	-108.90%
2019-12-31	₩-13.03 Billion ≈ $-8.83 Million	₩-81.33 Billion ≈ $-55.12 Million	6.244x	+359.13%
2018-12-31	₩58.63 Billion ≈ $39.73 Million	₩-141.28 Billion ≈ $-95.74 Million	-2.410x	-15.76%
2017-12-31	₩47.24 Billion ≈ $32.02 Million	₩-98.34 Billion ≈ $-66.65 Million	-2.082x	-528.17%
2016-12-31	₩147.69 Billion ≈ $100.09 Million	₩-48.94 Billion ≈ $-33.17 Million	-0.331x	--

About Sk Biopharmaceuticals Co Ltd

KO:326030 Korea Biotechnology

Market Cap

$4.64 Billion

₩6.84 Trillion KRW

Market Cap Rank

#3654 Global

#76 in Korea

Share Price

₩87400.00

Change (1 day)

+0.81%

52-Week Range

₩69400.00 - ₩140700.00

All Time High

₩217000.00